Articles & Research
from hVIVO

Infectious Diseases Blog – ‘The Pathogenda’ Part 4

So we know, or at least it is being widely reported, that depression and anxiety indices are raised worldwide, and most especially in High Income Countries (HIC). Whilst this is...

Scientific Paper

Human infection studies: Key considerations for challenge agent development and production

Infectious Diseases Blog – ‘The Pathogenda’ Part 3

Spring continues to bring its oft’ mixed blessings of sunshine and showers, as expressed over four hundred years ago in this short poem by Thomas Tusser in ‘A Hundred Good...

Infectious Diseases Blog – ‘The Pathogenda’ Part 2

Hello and welcome all to a sunny spring but one somewhat diminished in its capacity for ‘joy in the morning’ by a vicious uptick in BA.2 infections globally, with the...

Scientific Paper

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults

Infectious Diseases Blog – ‘The Pathogenda’ Part 1

Scientific Paper

EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge

hLab – Virology Laboratory Services

The annual challenge of the global health community is progressing innovative products (vaccines, antiviral drugs, immunomodulators) for the control of infections of significant disease burden in a timely manner at...

Human Challenge Trials as a tool in raising funding

Introduction challenge trials In human challenge studies (HCT) or Controlled Human Infection Models (CHIM), healthy volunteers are administered a pathogenic or virulent strain of a challenge agent, which can be...